On Friday, Following Stocks were among the “Top 100 Losers” In U.S. Stock Exchange: Pengrowth Energy (NYSE:PGH), MEI Pharma (NASDAQ:MEIP), W&T Offshore, (NYSE:WTI), Sagent Pharmaceuticals (NASDAQ:SGNT)
Pengrowth Energy Corp (USA) (NYSE:PGH) disclose that its April 15, 2015 cash dividend will be Cdn $0.02 for each ordinary share. The ex-dividend date is March 19, 2015. The dividend will be due to all shareholders who hold Pengrowth shares at the close of business on the record date of March 23, 2015.
Pengrowth Energy Corp (USA) (NYSE:PGH)’s shares picked down -5.05%, and closed at $3.01. The stock volatility for the week is 6.59%, while for the month remained 5.23%. The company holds consensus target price of $4.77.
If we consider EPS growth of the company, then the company indicated the following observations:
The company showed -0.87 diluted EPS growth for trailing twelve months. However, YTD EPS growth remained -79.20% and Annual EPS growth for the past 5 years is considered as -28.30%.
The mean recommendation of analysts for this stock is 2.40. (Where 1=Buy, 5=Sale).
Pengrowth Energy Corp (USA) (PGH) engages in the acquisition, development, exploration, and production of oil and natural gas assets in the Alberta, British Columbia, Saskatchewan, and Nova Scotia provinces in Canada. It primarily explores for crude oil, bitumen, natural gas, and natural gas liquids.
MEI Pharma Inc (NASDAQ:MEIP) an oncology company focused on the clinical development of novel therapies for cancer, disclosed top-line data from a randomized Phase II clinical study of its investigational drug candidate Pracinostat in combination with azacitidine in patients with previously untreated intermediate-2 or high-risk myelodysplastic syndrome (MDS). The double-blind, placebo-controlled study enrolled a total of 102 patients, randomized one-to-one, at 19 sites in the U.S.
MEI Pharma Inc (NASDAQ:MEIP) declined -4.92%, and closed at $1.74. The company has the market capitalization of $57.93 million. The beta value of the stock is 1.50. On the other hand the stock’s volatility for the week is 9.46%, and for the month is 7.04%. The stock’s price to book ratio is $1.93. Analyst’s mean recommendation regarding this stock is 2.70. (Where 1=Buy, 5=Sale).
MEI Pharma Inc (MEIP) an oncology company, focuses on the clinical development of novel therapies for the cure of cancer. The company’s lead drug candidate is Pracinostat, an orally available histone deacetylase inhibitor, which is in Phase II clinical test for the treatment of hematologic diseases, such as myelodysplastic syndrome and acute myeloid leukemia.
W&T Offshore, Inc. (NYSE:WTI) disclosed its year-end 2014 proved reserves, fourth quarter and full year 2014 operations and financial results, 2015 capital budget and drilling plans, and 2015 production and expense guidance. Some of the highlights include: WTI proved reserves at year-end 2014 were 120 million barrels of oil equivalent (“Boe”) with a PV-10 value of $2.6 billion, excluding the effect of estimated asset retirement obligations. Both the amount and value of our proved reserves have increased over the prior year even with our continued focus on longer-term projects.
W&T Offshore, Inc. (NYSE:WTI) decreased -4.79%, and closed at $5.17. The company holds the market capitalization of $392.40 million. For the last twelve months, the stock was able to keep return on equity at -0.10%, in response to its return on investment at 3.60%. Its 20-day moving average decreased -6.46%, below 50-day moving average of -10.19%, below 200-day moving average of -47.92% from the latest market price of $5.17. The mean recommendation of analysts for this stock is 2.70. (Where 1=Buy, 5=Sale).
W&T Offshore, Inc. (WTI) an independent oil and natural gas producer, together with its subsidiaries, engages in the acquisition, exploration, and development of oil and natural gas properties primarily in the Gulf of Mexico and onshore in the Permian Basin of West Texas. I
The Board of Directors of Sagent Pharmaceuticals Inc (NASDAQ:SGNT) a leader of specialty pharmaceutical products with a specific emphasis on the injectable market, disclosed that Jeffrey Yordon, Chairman and Chief Executive Officer, has informed the Board of his decision to retire from the Company. He will remain a member of the Board. Frank Kung, Ph.D., a well-regarded industry executive and a member of Sagent’s Board since 2006, has been named Chairman. The Board will immediately begin the search for a new CEO. In the interim, the Board has formed an Executive Management Committee to lead the Company.
Sagent Pharmaceuticals Inc (NASDAQ:SGNT) fell -4.68%, and closed at $22.83. The stock has the beta value of 1.41, and its volatility for the week is 7.93%, while for the month it is 4.36%. The company has the market capitalization of $363.44 million. The company holds the book value per share of 8.63, whereas cash per share is 2.31. Price to book ratio remained 2.65, while price to sale ratio is 2.53. Analysts mean recommendation for the stock is said to be 2.90 (where 1=Buy, 5=sale).
Sagent Pharmaceuticals Inc (SGNT) a specialty pharmaceutical company, develops, sources, manufactures, and markets pharmaceutical products, principally injectable-based generic equivalents to branded products in North America.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The data demonstrated in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
